Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is It Too Late to Buy Novavax Stock?

TheMotleyFool

0 0

Early investors in COVID-19 vaccine makers Moderna and Novavax (NASDAQ: NVAX) have earned significant returns over the past couple of years, with both stocks up over 1,000% since the start of 2020 (the S&P 500 has only risen by 44% during that time frame). Novavax's 4,000% returns are astronomical even though the company's vaccine hasn't yet gotten the go-ahead from the U.S. Food and Drug Administration (FDA) -- in fact, it hasn't even filed for an Emergency Use Authorization (EUA) yet.

It's a risky stock to be holding, but the good news is investors can hedge their positions. However, if you don't already have Novavax in your portfolio, is it worth taking a chance on the stock today?

Image source: Getty Images

Source Fool.com

Like: 0

NVAX

Share